Home > Insider Trading > Filing (0000950142-12-001610)

Filing Details

Accession Number:: 0000950142-12-001610
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-07-25 17:11:02
Reporting Period:: 2012-07-24

Filing Date:: 2012-07-25
Accepted Time:: 2012-07-25 17:11:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1544116	Durata Therapeutics Inc.	DRTX	Pharmaceutical Preparations (2834)	871247903

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1120478	Md A Dov Goldstein	888 Seventh Avenue, 30Th Floor New York NY 10106		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-07-24	2,019,713	$0.00	2,019,713	No	4	C	Indirect	By Aisling Capital III, LP
Common Stock	Acquisiton	2012-07-24	1,111,111	$9.00	3,130,824	No	4	P	Indirect	By Aisling Capital III, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Aisling Capital III, LP
No	4	P	Indirect	By Aisling Capital III, LP

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2012-07-24	16,157,707	$0.00	2,019,713	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

On July 24, 2012, Aisling Capital III, LP ("Aisling") acquired 2,019,713 shares of common stock issued upon the conversion of 16,157,707 shares of Series A Preferred Stock at the closing of Durata Therapeutics, Inc.'s initial public offering of common stock ("IPO") for no additional cost.
These shares of common stock are owned directly by Aisling, and held indirectly by Aisling Capital Partners III, LP ("Aisling GP") , as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling partners (the "Managers"). Dr. Goldstein is a member of the investment committee of Aisling and is a member of the Board of Directors of Durata Therapeutics, Inc. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest.
On July 24, 2012, Aisling acquired 1,111,111 shares of common stock in the IPO.
Series A preferred stock was convertible into common stock at the option of the holder or upon the completion of the IPO and had no expiration date.
Series A preferred stock was owned directly by Aisling, and held indirectly by Aisling GP, as general partner of Aisling, Aisling Partners, as general partner of Aisling GP, and each of the Managers. After the conversion of Series A preferred stock reported hereby, Aisling, Aisling GP, Aisling Partners and each of the Managers no longer hold any shares of Series A preferred stock. Dr. Goldstein is a member of the investment committee of Aisling and is a member of the Board of Directors of Durata Therapeutics, Inc. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he was the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest.